Literature DB >> 24125438

Role of the QuantiFERON®-TB Gold In-Tube test in the diagnosis of intrathoracic childhood tuberculosis.

R Lodha1, A Mukherjee, D Saini, S Saini, V Singh, S Singh, H M S Grewal, S K Kabra.   

Abstract

SETTING: Tertiary care hospitals in India.
OBJECTIVE: To compare the performance of the QuantiFERON®-TB Gold In-Tube test (QFT-GIT) with that of the tuberculin skin test (TST) in the diagnosis of intrathoracic childhood tuberculosis (TB).
METHODS: Children with intrathoracic TB were enrolled in a randomised controlled trial studying micronutrient supplementation in intrathoracic TB. They underwent TST and QFT-GIT before starting daily anti-tuberculosis treatment.
RESULTS: Of 362 children (median age 115.5 months, IQR 73-144, 55% girls) enrolled in the study, microbiological confirmation of TB was obtained in 128 (35%). The TST was positive in 337 (93%, 95%CI 90-95.5) and QFT-GIT in 297 (82%, 95%CI 77.8-85.6). Sensitivity of TST and QFT-GIT in culture-confirmed TB cases was respectively 90.5% (95%CI 84.1-94.5) and 82.6% (95%CI 74.9-88.4). QFT-GIT positivity rate correlated with TST induration (P < 0.001). TST was influenced by the disease spectrum (P = 0.004) and the age of the children (P = 0.002); QFT-GIT remained unaffected by these factors. Bacille Calmette-Guérin immunisation status, weight-for-age Z-scores and microbiological confirmation of Mycobacterium tuberculosis did not influence the performance of either test.
CONCLUSION: In high-burden countries, QFT-GIT is comparable to TST and offers no added advantage in the diagnosis of childhood intrathoracic TB.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125438     DOI: 10.5588/ijtld.13.0348

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Authors:  Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill
Journal:  Lancet Respir Med       Date:  2017-02-16       Impact factor: 30.700

2.  Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles.

Authors:  S Dhanasekaran; S Jenum; R Stavrum; C Ritz; J Kenneth; M Vaz; T M Doherty; H M S Grewal
Journal:  Genes Immun       Date:  2014-04-17       Impact factor: 2.676

Review 3.  Childhood tuberculosis in general practice.

Authors:  Prawin Kumar; Amber Kumar; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2014-10-05       Impact factor: 1.967

4.  Effect of micronutrient deficiency on QuantiFERON-TB Gold In-Tube test and tuberculin skin test in diagnosis of childhood intrathoracic tuberculosis.

Authors:  A Mukherjee; S Saini; S K Kabra; N Gupta; V Singh; S Singh; S Bhatnagar; D Saini; H M S Grewal; R Lodha
Journal:  Eur J Clin Nutr       Date:  2013-10-30       Impact factor: 4.016

5.  Performance of interferon-γ release assays in the diagnosis of confirmed active tuberculosis in immunocompetent children: a new systematic review and meta-analysis.

Authors:  Patrizia Laurenti; Matteo Raponi; Chiara de Waure; Marta Marino; Walter Ricciardi; Gianfranco Damiani
Journal:  BMC Infect Dis       Date:  2016-03-18       Impact factor: 3.090

6.  Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children-A Systematic Review and Meta-Analysis.

Authors:  Noëmi R Meier; Thomas Volken; Marc Geiger; Ulrich Heininger; Marc Tebruegge; Nicole Ritz
Journal:  Front Pediatr       Date:  2019-05-29       Impact factor: 3.418

7.  Agreement between QuantiFERON®-TB Gold In-Tube and the tuberculin skin test and predictors of positive test results in Warao Amerindian pediatric tuberculosis contacts.

Authors:  Lilly M Verhagen; Mailis Maes; Julian A Villalba; Adriana d'Alessandro; Lazaro Perez Rodriguez; Mercedes F España; Peter W M Hermans; Jacobus H de Waard
Journal:  BMC Infect Dis       Date:  2014-07-11       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.